Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (51-60 of 578) with videos related to

Pageof 58
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 27, 2017
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancerAdriaan Vanderstichele, Pieter Busschaert, Siel Olbrecht, et al.
The Journal of Reproductive Medicine|November 9, 2018
Choriocarcinoma in Situ in a Partial Hydatidiform Mole A: Case ReportThais Baert, Joris Vermeesch, Dirk Timmerman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2014
Psychologic, relational, and sexual functioning in women after surgical treatment of vulvar malignancy: a prospective controlled studyLeen Aerts, Paul Enzlin, Johan Verhaeghe, et al.
Journal of Minimally Invasive Gynecology|October 31, 2008
The addition of 4% oxygen to the CO(2) pneumoperitoneum does not decrease dramatically port site metastasesJasper Verguts, Ignace Vergote, Frederic Amant, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 3, 2017
Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case ReportAnne-Sophie Van Rompuy, Adriaan Vanderstichele, Ignace Vergote, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|April 13, 2018
Quality of Life Considerations in Gynecologic CancerRichard T Penson, Lari B Wenzel, Ignace Vergote, et al.
Expert Review of Anticancer Therapy|June 23, 2025
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinomaRobert L Coleman, Pratheek Kalyanapu, Christopher J Walker, et al.
Gynecologic Oncology|August 2, 2003
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesisFrederic Amant, Veerle Vloeberghs, Heidi Woestenborghs, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 28, 2009
Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literatureFrédéric Amant, An Coosemans, Vincent Renard, et al.
Gynecologic Oncology|February 15, 2003
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II studyNina Keldsen, Hanne Havsteen, Ignace Vergote, et al.
Pageof 58

Showing results (51-60 of 578) with videos related to

Sort By:
Pageof 58
European Journal of Cancer (Oxford, England : 1990)|September 27, 2017
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancerAdriaan Vanderstichele, Pieter Busschaert, Siel Olbrecht, et al.
The Journal of Reproductive Medicine|November 9, 2018
Choriocarcinoma in Situ in a Partial Hydatidiform Mole A: Case ReportThais Baert, Joris Vermeesch, Dirk Timmerman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2014
Psychologic, relational, and sexual functioning in women after surgical treatment of vulvar malignancy: a prospective controlled studyLeen Aerts, Paul Enzlin, Johan Verhaeghe, et al.
Journal of Minimally Invasive Gynecology|October 31, 2008
The addition of 4% oxygen to the CO(2) pneumoperitoneum does not decrease dramatically port site metastasesJasper Verguts, Ignace Vergote, Frederic Amant, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 3, 2017
Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case ReportAnne-Sophie Van Rompuy, Adriaan Vanderstichele, Ignace Vergote, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|April 13, 2018
Quality of Life Considerations in Gynecologic CancerRichard T Penson, Lari B Wenzel, Ignace Vergote, et al.
Expert Review of Anticancer Therapy|June 23, 2025
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinomaRobert L Coleman, Pratheek Kalyanapu, Christopher J Walker, et al.
Gynecologic Oncology|August 2, 2003
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesisFrederic Amant, Veerle Vloeberghs, Heidi Woestenborghs, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 28, 2009
Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literatureFrédéric Amant, An Coosemans, Vincent Renard, et al.
Gynecologic Oncology|February 15, 2003
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II studyNina Keldsen, Hanne Havsteen, Ignace Vergote, et al.
Pageof 58